STOK - Stoke Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
759M
Enterprise Value 3
593.71M
Trailing P/E
N/A
Forward P/E 1
-15.16
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
3.25
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-20.64

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-97.90%
S&P500 52-Week Change 325.86%
52 Week High 31,200.00
52 Week Low 319.21
50-Day Moving Average 325.69
200-Day Moving Average 326.25

Share Statistics

Avg Vol (3 month) 3142.73k
Avg Vol (10 day) 3116.11k
Shares Outstanding 532.73M
Float 10.19M
% Held by Insiders 11.29%
% Held by Institutions 1100.06%
Shares Short (Dec 30, 2019) 41.36M
Short Ratio (Dec 30, 2019) 48.32
Short % of Float (Dec 30, 2019) 49.47%
Short % of Shares Outstanding (Dec 30, 2019) 44.16%
Shares Short (prior month Nov 28, 2019) 41.1M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -28.77M
Net Income Avi to Common (ttm)-26.45M
Diluted EPS (ttm)-2.66
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)233.05M
Total Cash Per Share (mrq)7.12
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)48.15
Book Value Per Share (mrq)7.14

Cash Flow Statement

Operating Cash Flow (ttm)-24.37M
Levered Free Cash Flow (ttm)N/A